New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect early Ketone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and delays in intervention Nearly 60% of pediatric hospitalizations for Type 1 diabetes in the U.S. are associated with DKA1 ABBOTT PARK, Ill., June 6, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes.

PRNewsWire • 4 hours ago

Abbott Labs must face lawsuit over PediaSure children's growth claims

Abbott Laboratories must defend against a proposed class-action lawsuit claiming it misled consumers into believing its PediaSure Grow & Gain nutrition ​drinks were "clinically proven" to help children grow taller, a federal judge ‌ruled on Thursday.

Reuters • Jun 4, 2026

Abbott Addresses a Major Diabetes Care Gap With Tech Innovation

ABT wins the CE Mark for Libre Duo sensors that track glucose and ketones every minute, aiming to spot DKA risks earlier and reduce routine testing.

Zacks Investment Research • Jun 4, 2026

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't

Buffett, as CEO of Berkshire Hathaway, delivered six decades of market-beating returns. Abel took over the CEO role in January and aims to follow the path traced by the investing giant.

The Motley Fool • Jun 3, 2026

Abbott's CE Mark Win for Libre Duo Systems May Lift Its Stock

ABT wins CE Mark for Libre Duo systems, the first dual glucose-ketone sensors, enabling real-time monitoring as European rollout begins later this year.

Zacks Investment Research • Jun 1, 2026

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • May 29, 2026

BSX vs. ABT: Which Medical Stock Has More Upside Potential?

Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.

Zacks Investment Research • May 29, 2026

Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks Investment Research • May 28, 2026

ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

Cologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guideline Abbott to offer only CRC screening portfolio aligned to new ACS recommendations combining preferred stool-based plus additional blood-based options Recent publications support Cologuard-first strategy, demonstrating better outcomes for patients, providers, health systems, and payers ABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive screening options for adults age 45 and older who are at average risk for CRC.

PRNewsWire • May 27, 2026

Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetes Integrates with the Libre digital health ecosystem, allowing people to share glucose and ketone data with caregivers and healthcare providers Designed for compatibility with leading automated insulin delivery (AID) systems ABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology for people with diabetes.

PRNewsWire • May 27, 2026